Nonmydriatic Handheld Fundus Cameras Market
Global Nonmydriatic Handheld Fundus Cameras Strategic Research Report 2024: Market to Reach $259 Million by 2030 - Glaucoma Prevalence and Need for Screening to Fuel Sales
May 23, 2024 11:08 ET | Research and Markets
Dublin, May 23, 2024 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Nonmydriatic...
Clearside Logo 2024.jpg
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
May 21, 2024 07:05 ET | Clearside Biomedical, Inc.
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience Support...
22157.jpg
Global Uveitis Treatment Research Report 2024: Market to Reach $1.34 Billion by 2034, Fueled by Increased Prevalence, Treatment Improvements, and Strategic Alliances & Collaborations
May 16, 2024 10:30 ET | Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Global Uveitis Treatment Market" report has been added to ResearchAndMarkets.com's offering.The global uveitis treatment market accounted for USD 753...
Clearside Logo 2024.jpg
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:05 ET | Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast...
Clearside Logo 2024.jpg
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
May 08, 2024 16:15 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Logo 2024.jpg
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 12, 2024 16:05 ET | Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened...
22157.jpg
Global Macular Degeneration Treatment Market Forecast to 2031: Breakthrough in Durable Anti-VEGF Drugs Redefines Patient Care with Less Frequent Dosing
January 26, 2024 06:27 ET | Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade,...
Global Retinal Biologics Market
Retinal Biologics Global Market Report 2023: Innovations Key to Future Advances - Long-term Forecasts to 2028 and 2033
January 25, 2024 09:33 ET | Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Retinal Biologics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. Profound analytics indicate that the...
22157.jpg
Retinopathy of Prematurity Research Reveals Market Insights, Epidemiology, and Forecast to 2032
January 24, 2024 10:49 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Retinopathy of Prematurity - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
logo color s and clearside.jpg
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 16:05 ET | Clearside Biomedical, Inc.
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5...